JP2008525342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525342A5 JP2008525342A5 JP2007547323A JP2007547323A JP2008525342A5 JP 2008525342 A5 JP2008525342 A5 JP 2008525342A5 JP 2007547323 A JP2007547323 A JP 2007547323A JP 2007547323 A JP2007547323 A JP 2007547323A JP 2008525342 A5 JP2008525342 A5 JP 2008525342A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- antibody
- factor xii
- protease
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 claims 9
- 208000007536 Thrombosis Diseases 0.000 claims 6
- 108010039627 Aprotinin Proteins 0.000 claims 4
- 235000000832 Ayote Nutrition 0.000 claims 4
- 235000009854 Cucurbita moschata Nutrition 0.000 claims 4
- 240000001980 Cucurbita pepo Species 0.000 claims 4
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 claims 4
- 108010080865 Factor XII Proteins 0.000 claims 4
- 102000000429 Factor XII Human genes 0.000 claims 4
- 108010071241 Factor XIIa Proteins 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 4
- 235000015136 pumpkin Nutrition 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 3
- 230000006641 stabilisation Effects 0.000 claims 3
- 238000011105 stabilization Methods 0.000 claims 3
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 108010087765 Antipain Proteins 0.000 claims 2
- 241000208173 Apiaceae Species 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- 102000055157 Complement C1 Inhibitor Human genes 0.000 claims 2
- 108700040183 Complement C1 Inhibitor Proteins 0.000 claims 2
- 101710194146 Ecotin Proteins 0.000 claims 2
- 230000026769 Factor XII activation Effects 0.000 claims 2
- -1 Fmoc-Ala-Pyr-CN Chemical compound 0.000 claims 2
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 claims 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 2
- 229940122055 Serine protease inhibitor Drugs 0.000 claims 2
- 101710102218 Serine protease inhibitor Proteins 0.000 claims 2
- 101710112924 Trypsin inhibitor 5 Proteins 0.000 claims 2
- 108010059382 Zea mays trypsin inhibitor Proteins 0.000 claims 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 claims 2
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 239000002506 anticoagulant protein Substances 0.000 claims 2
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 claims 2
- 229960004405 aprotinin Drugs 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 claims 2
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 claims 2
- 108010052968 leupeptin Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003649 prolyl endopeptidase inhibitor Substances 0.000 claims 2
- 239000003001 serine protease inhibitor Substances 0.000 claims 2
- 206010001935 American trypanosomiasis Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 208000024699 Chagas disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 241000223104 Trypanosoma Species 0.000 claims 1
- 241000223109 Trypanosoma cruzi Species 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000002917 arthritic effect Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 230000024203 complement activation Effects 0.000 claims 1
- 230000020764 fibrinolysis Effects 0.000 claims 1
- 208000021822 hypotensive Diseases 0.000 claims 1
- 230000001077 hypotensive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04030593 | 2004-12-23 | ||
| EP04030593.0 | 2004-12-23 | ||
| PCT/EP2005/013714 WO2006066878A1 (en) | 2004-12-23 | 2005-12-20 | Prevention of thrombus formation and/or stabilization |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525342A JP2008525342A (ja) | 2008-07-17 |
| JP2008525342A5 true JP2008525342A5 (enExample) | 2009-02-19 |
| JP5118492B2 JP5118492B2 (ja) | 2013-01-16 |
Family
ID=34927953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007547323A Expired - Lifetime JP5118492B2 (ja) | 2004-12-23 | 2005-12-20 | 血栓の形成の防止および／または安定化の防止 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8119137B2 (enExample) |
| EP (2) | EP2272565A3 (enExample) |
| JP (1) | JP5118492B2 (enExample) |
| KR (1) | KR101277097B1 (enExample) |
| CN (1) | CN101102819A (enExample) |
| AU (1) | AU2005318464B2 (enExample) |
| BR (1) | BRPI0519349A8 (enExample) |
| CA (1) | CA2591786C (enExample) |
| DK (1) | DK1830924T3 (enExample) |
| ES (1) | ES2407965T3 (enExample) |
| MX (1) | MX2007006997A (enExample) |
| PL (1) | PL1830924T3 (enExample) |
| RU (1) | RU2514878C2 (enExample) |
| WO (1) | WO2006066878A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057287A (en) | 1994-01-11 | 2000-05-02 | Dyax Corp. | Kallikrein-binding "Kunitz domain" proteins and analogues thereof |
| ES2528254T3 (es) | 2002-06-07 | 2015-02-05 | Dyax Corp. | Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico |
| US7153829B2 (en) | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| DK1542710T3 (da) | 2002-08-28 | 2012-10-15 | Dyax Corp | Fremgangsmåde til konservering af organer og væv |
| US7235530B2 (en) | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
| GB0607515D0 (en) * | 2006-04-13 | 2006-05-24 | Axis Shield Diagnostics Ltd | Anti-factor xlla therapy |
| WO2008016883A2 (en) | 2006-07-31 | 2008-02-07 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DK2526962T3 (da) * | 2007-02-12 | 2019-10-07 | Csl Behring Gmbh | Therapeutic application of Kazal-type serine protease inhibitors |
| WO2009026539A1 (en) * | 2007-08-23 | 2009-02-26 | Genzyme Corporation | Treatment with kallikrein inhibitors |
| EP2215256A1 (en) * | 2007-10-22 | 2010-08-11 | Georg Dewald | Disorders of vasoregulation and methods of diagnosing them |
| EP2103311A1 (en) | 2008-03-20 | 2009-09-23 | CSL Behring GmbH | The calcium sensor STIM1 is essential for pathological thrombus formation |
| EP2145900A1 (en) | 2008-07-15 | 2010-01-20 | CSL Behring GmbH | Orai1 (CRACM1) is the platelet SOC channel and essential for pathological thrombus formation |
| WO2010080833A1 (en) | 2009-01-06 | 2010-07-15 | Dyax Corp. | Treatment of mucositis with kallikrein inhibitors |
| EP2269597A1 (en) | 2009-06-22 | 2011-01-05 | CSL Behring GmbH | CLEC-2 is an essential platelet activating receptor in hemostasis and thrombosis |
| EP2272874A1 (en) | 2009-07-10 | 2011-01-12 | CSL Behring GmbH | Role of PLD1 in thrombus formation and integrin alpha IIb beta 3 activation |
| HRP20220107T1 (hr) | 2010-01-06 | 2022-04-15 | Takeda Pharmaceutical Company Limited | Proteini koji vežu kalikrein plazme |
| EP2371857A1 (en) * | 2010-04-01 | 2011-10-05 | CSL Behring GmbH | Factor XII inhibitors for treating interstitial lung disease |
| US9150864B2 (en) * | 2010-11-08 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| KR102107695B1 (ko) | 2011-01-06 | 2020-05-07 | 다이액스 코포레이션 | 혈장 칼리크레인 결합 단백질 |
| EP2497489A1 (en) * | 2011-03-09 | 2012-09-12 | CSL Behring GmbH | Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs |
| CN103415301A (zh) * | 2011-03-09 | 2013-11-27 | 德国杰特贝林生物制品有限公司 | 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂 |
| WO2012170947A2 (en) | 2011-06-10 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Methods for modulating factor 12 expression |
| EP2548892A1 (en) | 2011-07-22 | 2013-01-23 | CSL Behring GmbH | Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses |
| JP6253578B2 (ja) * | 2011-07-22 | 2017-12-27 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 阻害性抗第ｘｉｉ／ｘｉｉａ因子モノクローナル抗体及びそれらの使用 |
| WO2013028069A1 (en) * | 2011-08-23 | 2013-02-28 | Synapse B.V. | Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces. |
| EP2623110A1 (en) | 2012-01-31 | 2013-08-07 | CSL Behring GmbH | Factor XII inhibitors for the treatment of neurological inflammatory disorders |
| WO2014089493A1 (en) * | 2012-12-07 | 2014-06-12 | Vanderbilt University | Antibodies against factor xii and uses thereof |
| CA2901225C (en) | 2013-03-08 | 2023-09-19 | Csl Behring Gmbh | Treatment and prevention of remote ischemia-reperfusion injury |
| KR20160026905A (ko) * | 2013-06-28 | 2016-03-09 | 체에스엘 베링 게엠베하 | 인자 ｘｉｉ 억제제 및 ｃ1-억제제를 이용한 병용 치료요법 |
| AU2015276089B2 (en) | 2014-06-18 | 2021-03-18 | Csl Behring Gmbh | Therapy using a Factor XII inhibitor in a neurotraumatic disorder |
| US11390687B2 (en) | 2015-01-02 | 2022-07-19 | Takeda Pharmaceutical Company Limited | Bispecific antibodies against plasma kallikrein and Factor XII |
| CA2982413A1 (en) * | 2015-04-28 | 2016-11-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Novel inhibitors of the enzyme activated factor xii (fxiia) |
| AU2016297018B9 (en) | 2015-07-21 | 2022-12-01 | Takeda Pharmaceutical Company Limited | A monoclonal antibody inhibitor of factor XIIa |
| EP3387018A1 (en) | 2015-12-11 | 2018-10-17 | Dyax Corp. | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
| EP3440107A4 (en) | 2016-04-06 | 2020-02-19 | CSL Limited | METHOD FOR TREATING ATHEROSCLEROSIS |
| AU2018382222B2 (en) | 2017-12-15 | 2025-09-04 | Csl Limited | Use of a FXIIa-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease |
| CN112437682B (zh) | 2018-06-19 | 2024-11-05 | 里珍纳龙药品有限公司 | 抗因子XII/XIIa抗体和其用途 |
| US12134657B2 (en) | 2018-11-28 | 2024-11-05 | Oregon Health & Science University | Therapeutic factor XII antibody |
| BR112022000113A2 (pt) | 2019-07-08 | 2022-03-15 | Activesite Pharmaceuticals Inc | Processos para preparação de inibidores de calicreí-na de plasma |
| AU2021209045A1 (en) | 2020-01-13 | 2022-07-28 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| US20240352150A2 (en) * | 2020-06-16 | 2024-10-24 | Ningbo Comgen Biotech Co., Ltd. | Anti-factor xii (fxii) nanobody or antigen-binding fragment thereof, and use thereof |
| CN116670280A (zh) | 2020-12-18 | 2023-08-29 | Ionis 制药公司 | 用于调节因子xii的化合物和方法 |
| AU2024291721A1 (en) | 2023-07-19 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK225488D0 (da) * | 1988-04-26 | 1988-04-26 | Novo Industri As | Polypeptid |
| US4963657A (en) * | 1988-06-09 | 1990-10-16 | Temple University Of The Commonwealth System Of Higher Education | Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same |
| WO1994020535A1 (en) | 1992-12-11 | 1994-09-15 | Corvas International, Inc. | ECOTIN AS A FACTOR Xa, XIa, AND XIIa INHIBITOR |
| CA2170030A1 (en) | 1993-09-14 | 1995-03-23 | Robert A. Lazarus | Pharmaceutical compositions containing ecotin and homologs thereof |
| ZA963619B (en) * | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
| DE19725014A1 (de) * | 1997-06-13 | 1998-12-17 | Bayer Ag | Aprotininvarianten mit verbesserten Eigenschaften und Bikunine von Aprotininvarianten |
| GB9800817D0 (en) | 1998-01-16 | 1998-03-11 | Bio Discovery Ltd | Serine protease inhibitors |
| ATE274600T1 (de) * | 1998-06-08 | 2004-09-15 | Univ Vermont | Verfahren zur bestimmung der blutgerinnung in plasma |
| JP2002525298A (ja) * | 1998-09-28 | 2002-08-13 | メルク エンド カムパニー インコーポレーテッド | トロンビン阻害剤の投与による炎症疾患の処置法 |
| ATE468136T1 (de) * | 2001-01-11 | 2010-06-15 | D Collen Res Foundation Vzw | Verfahren und pharmazeutische zusammensetzung zur vorbeugung und/oder behandlung des syndroms der systemischen entzündlichen reaktion |
| US7153829B2 (en) * | 2002-06-07 | 2006-12-26 | Dyax Corp. | Kallikrein-inhibitor therapies |
| ES2528254T3 (es) * | 2002-06-07 | 2015-02-05 | Dyax Corp. | Polipéptidos de dominio Kunitz modificado y su uso para reducir la isquemia o el inicio de una respuesta inflamatoria sistémica asociada con un procedimiento quirúrgico |
| WO2004004640A2 (en) | 2002-07-05 | 2004-01-15 | Tetragrammaton Inc. | Methods, compositions and kits for treating damage to excitable tissue |
| DK1542710T3 (da) * | 2002-08-28 | 2012-10-15 | Dyax Corp | Fremgangsmåde til konservering af organer og væv |
| US20040229778A1 (en) | 2003-05-13 | 2004-11-18 | Elmaleh David R. | Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases |
| WO2004110356A2 (en) | 2003-05-15 | 2004-12-23 | Cbr Institute For Biomedical Research, Inc. | Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity |
| DK1626736T3 (da) | 2003-05-16 | 2020-09-28 | Pharming Intellectual Property B V | C1-inhibitor med kort halveringstid til midlertidig behandling |
| US8152750B2 (en) | 2003-09-12 | 2012-04-10 | Marine Polymer Technologies, Inc. | Vascular access preservation in hemodialysis patients |
| GB0411145D0 (en) | 2004-05-19 | 2004-06-23 | Imp College Innovations Ltd | Protease inhibitors and their therapeutic applications |
| US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| GB0418877D0 (en) | 2004-08-24 | 2004-09-29 | Univ Edinburgh | Heart |
| US20060104944A1 (en) | 2004-11-18 | 2006-05-18 | Mousa Shaker A | Activators and inhibitors of protease activated receptor2 (PAR2) and methods of use |
| SI1669074T1 (sl) | 2004-12-01 | 2010-10-29 | Par Pharmaceuticals Inc | Uporaba megestrol acetata za izboljšanje delovanja srca in zdravljenje srčnega popuščanja |
-
2005
- 2005-12-20 CN CNA2005800465756A patent/CN101102819A/zh active Pending
- 2005-12-20 BR BRPI0519349A patent/BRPI0519349A8/pt not_active Application Discontinuation
- 2005-12-20 JP JP2007547323A patent/JP5118492B2/ja not_active Expired - Lifetime
- 2005-12-20 DK DK05820601.2T patent/DK1830924T3/da active
- 2005-12-20 EP EP10183075A patent/EP2272565A3/en not_active Withdrawn
- 2005-12-20 WO PCT/EP2005/013714 patent/WO2006066878A1/en not_active Ceased
- 2005-12-20 RU RU2007123797/14A patent/RU2514878C2/ru not_active Application Discontinuation
- 2005-12-20 MX MX2007006997A patent/MX2007006997A/es active IP Right Grant
- 2005-12-20 US US11/793,820 patent/US8119137B2/en active Active
- 2005-12-20 AU AU2005318464A patent/AU2005318464B2/en not_active Expired
- 2005-12-20 CA CA2591786A patent/CA2591786C/en not_active Expired - Lifetime
- 2005-12-20 ES ES05820601T patent/ES2407965T3/es not_active Expired - Lifetime
- 2005-12-20 PL PL05820601T patent/PL1830924T3/pl unknown
- 2005-12-20 EP EP05820601A patent/EP1830924B1/en not_active Expired - Lifetime
- 2005-12-20 KR KR1020077016992A patent/KR101277097B1/ko not_active Expired - Lifetime
-
2011
- 2011-12-29 US US13/339,793 patent/US20120148688A1/en not_active Abandoned
-
2012
- 2012-12-21 US US13/723,847 patent/US8715672B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525342A5 (enExample) | ||
| RU2007123797A (ru) | Предотвращение формирования и/или стабилизации тромбов | |
| Kenniston et al. | Inhibition of plasma kallikrein by a highly specific active site blocking antibody | |
| Mojcik et al. | Aprotinin and the systemic inflammatory response after cardiopulmonary bypass | |
| Mahdy et al. | Perioperative systemic haemostatic agents | |
| Weitz | Factor XI and factor XII as targets for new anticoagulants | |
| Gils et al. | Plasminogen activator inhibitor-1 | |
| Bryant et al. | Human plasma kallikrein-kinin system: physiological and biochemical parameters | |
| Viles-Gonzalez et al. | Links between inflammation and thrombogenicity in atherosclerosis | |
| Huber-Lang et al. | Auxiliary activation of the complement system and its importance for the pathophysiology of clinical conditions | |
| NO20091647L (no) | Trypsinlignende serinproteaseinhibitorer og deres fremstilling og anvendelse | |
| Burster et al. | Hindrance of the proteolytic activity of neutrophil-derived serine proteases by serine protease inhibitors as a management of cardiovascular diseases and chronic inflammation | |
| WO1996035788A3 (en) | Kunitz type protease inhibitors | |
| Vercauteren et al. | Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis | |
| Demoulin et al. | Dual inhibition of factor XIIa and factor XIa as a therapeutic approach for safe thromboprotection | |
| WO1994020526A1 (en) | Peptide boronic acid derivatives having protease inhibiting activity | |
| Flight et al. | Comparison of textilinin-1 with aprotinin as serine protease inhibitors and as antifibrinolytic agents | |
| JP6319592B2 (ja) | 静脈血栓状態の予防および治療のための、ブロメラインとナットウキナーゼとを含む線維素溶解組成物 | |
| Mukaiyama et al. | Abdominal aortic aneurysm complicated with chronic disseminated intravascular coagulopathy: a case of surgical treatment | |
| Jagneaux et al. | Coagulation in sepsis | |
| Mammen | Perspectives for the future | |
| Blat et al. | A renaissance for the contact system in blood coagulation? | |
| Hack | Derangements of coagulation and fibrinolysis in infectious diseases | |
| Renné et al. | Plasma kallikrein: novel functions for an old protease | |
| Lupu et al. | Plasmin‐dependent proteolysis of tissue factor pathway inhibitor in a mouse model of endotoxemia |